论文部分内容阅读
目的测定卵巢上皮性癌患者血清中HER-2/neu自身抗体的表达水平,探讨其作为卵巢上皮性癌血清学标志物的诊断价值。方法采用ELISA法检测2007年至2009年40例卵巢上皮性癌患者、20例良性上皮性卵巢肿瘤患者和20例正常对照女性的血清HER-2/neu自身抗体水平;采用统计学方法分析血清HER-2/neu自身抗体的诊断价值。结果卵巢上皮性癌患者血清HER-2/neu自身抗体水平显著高于良性上皮性卵巢肿瘤患者和正常女性(P<0.05)。ROC曲线分析显示HER-2/neu自身抗体用于卵巢上皮性癌诊断的灵敏度和特异性分别为47.5%和97.5%;联合CA125检测可提高诊断特异性至90%且不降低灵敏度。偏相关系数表明血清CA125与HER-2/neu自身抗体水平无相关性。结论血清HER-2/neu自身抗体水平与卵巢上皮性癌相关,有望成为卵巢上皮性癌诊断的一种新血清学标志物。
Objective To determine the expression level of HER-2 / neu autoantibodies in the serum of patients with epithelial ovarian cancer and to evaluate its diagnostic value as a serological marker of ovarian epithelial cancer. Methods Serum HER-2 / neu autoantibodies were detected by ELISA in 40 patients with epithelial ovarian cancer, 20 patients with benign epithelial ovarian tumors and 20 normal controls from 2007 to 2009. Serum HER -2 / neu autoantibodies. Results Serum levels of HER-2 / neu autoantibodies in patients with epithelial ovarian cancer were significantly higher than those in benign epithelial ovarian tumors and normal women (P <0.05). ROC curve analysis showed that the sensitivity and specificity of HER-2 / neu autoantibodies for the diagnosis of epithelial ovarian cancer were 47.5% and 97.5%, respectively; the combination of CA125 test increased diagnostic specificity to 90% with no decrease in sensitivity. Partial correlation coefficient showed no correlation between serum CA125 and HER-2 / neu autoantibodies. Conclusions Serum levels of HER-2 / neu autoantibodies correlate with epithelial ovarian cancer and are expected to become a new serological marker for the diagnosis of epithelial ovarian cancer.